LEAD 452
Alternative Names: LEAD-452Latest Information Update: 12 Sep 2022
At a glance
- Originator LeadArtis
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins; Single-domain antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; Tumour necrosis factor receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; Colorectal cancer; Head and neck cancer; Lung cancer
Most Recent Events
- 07 Sep 2022 Preclinical trials in Breast cancer in Spain (Parenteral), prior to September 2022 (LeadArtis pipeline, September 2022)
- 07 Sep 2022 Preclinical trials in Colorectal cancer in Spain (Parenteral), prior to September 2022 (LeadArtis pipeline, September 2022)
- 07 Sep 2022 Preclinical trials in Head and neck cancer in Spain (Parenteral), prior to September 2022 (LeadArtis pipeline, September 2022)